Bioprinted organs soon could revolutionize clinical trials, transplantation, and regenerative medicine. However, several technical hurdles must be navigated for biopharmaceutical companies to successfully harness and commercialize three-dimensional (3D) printing for such purposes.
In this BioProcess International interview, Lev Gerlovin, Andrew Thomson, and Jack Vailas, along with Bill Whitford of GE Healthcare Life Sciences, discuss persistent printing problems and analyze promising solutions raised by Chris Lo in a recent GlobalData: Medical Technology report (November 2019) entitled “The Long Road to Reliable Organ Printing.”
To read the interview, download the PDF below.
Articles
Better bioprinting ahead: Breakthroughs and remaining challenges
March 20, 2020
Key contacts
Upcoming events
Informa: EU Pharmaceutical Law Forum 2026
CRA is a proud sponsor the event featuring authority insights from the EU Commission, Competition Authorities, EMA and leading pharmaceutical...
ThoughtLeaders4: 3rd Annual UK Competition Law
CRA is a proud sponsor of the summit. Simon Chisholm is a speaker during the session titled “Understanding Lessons and Takeaways from Market Investigations”...